随着减重药巨头诺和诺德重磅GLP-1类药物司美格鲁肽在中国的核心分子专利即将于3月到期，一大批中国本土的司美格鲁肽仿制药正在获批路上。据公开信息，目前国内市场上包括九源基因、丽珠集团、华东医药、齐鲁制药、正大天晴在内的十多家本土制药公司的司美格鲁肽仿制药有望在不久的将来上市，还有十余款处于三期临床，一场价格大战即将席卷。一位内分泌专家表示，随着更多仿制药的上市，减重药很快就会迎来“白菜价”时代。（第一财经）
Most UK staff in Antarctica go there for the continent's summer
，这一点在同城约会中也有详细论述
既有战略层面的擘画，也有战术层面的部署。。业内人士推荐Line官方版本下载作为进阶阅读
When it comes to the president, chaos is often the strategy. For businesses like Smeaton’s the opposite is needed—stability. Wearing Morph suits might be fun and gain you 5 million views on YouTube. But a potential wipeout of your profits after the latest announcement from the White House is hardly a laughing matter.，详情可参考heLLoword翻译官方下载